Morgan Stanley lowered the firm’s price target on Mirion (MIR) to $27 from $29 and keeps an Equal Weight rating on the shares. The firm is updating and rolling forward estimates following the recent earnings report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIR:
- Mirion price target lowered to $30 from $33 at JPMorgan
- Mirion Technologies: Solid Nuclear and Medical Demand, Improving Margins, and Paragon Synergies Support Buy Rating and Mid-30% Upside Potential
- Omega takes new stake in Rocket Companies, exits ArriVent Biopharma
- Mirion Technologies Signals Confident Path to 2026
- Mirion price target lowered to $29 from $30 at Baird